-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:12 GMT
… non-small cell lung cancer following surgery and … Platform (ETOP).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … and paclitaxel followed by doxorubicin or epirubicin and …
-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:06 GMT
… non-small cell lung cancer following surgery and … Platform (ETOP).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … and paclitaxel followed by doxorubicin or epirubicin and …
-
Development and Validation of Coding Algorithms to Identify Patients with Incident Non-Small Cell Lung Cancer in United States Healthcare Claims Data
12 Jan 2023 04:31 GMT
… adults.3 Lung cancer is a heterogenous disease. Most lung cancers in the … (incident) small-cell lung cancer (SCLC) and other lung cancers, a 5% random sample … during this time period [cyclophosphamide, doxorubicin, irinotecan, vincristine, or topotecan]) …
-
Chemo in Afternoon Works Better Than in Morning, but Only in Women
31 Jan 2023 15:04 GMT
… treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP … melanoma and non–small cell lung cancer, survival outcomes improve with timed … to cyclophosphamide (10%; P = .002), doxorubicin (8%; P = .002), and rituximab …
-
Dual-Drug Nanosystem: Etoposide Prodrug and Cisplatin Coloaded Nanostructured Lipid Carriers for Lung Cancer Therapy
05 Dec 2022 09:10 GMT
… in lung tumor– … lung cancer combination therapy.Keywords: lung cancer, prodrug, etoposide, cisplatin, nanostructured lipid carriers
Introduction
Lung cancer … lung cancer (NSCLC; about 85%) and small-cell lung cancer … Lung cancer therapy using doxorubicin …
-
Cell-Based Drug Delivery Systems with Innate Homing Capability as a Novel Nanocarrier Platform
29 Jan 2023 00:13 GMT
… , a silica nanorattle-doxorubicin loaded drug carrier functionalized … , et al. Efficient lung cancer-targeted drug delivery via … al. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells … systemic treatment of metastatic lung cancer. Drug Deliv. 2017 …
-
Identification of Key Genes and FUNCTIONAL Pathway in Radioresistance of Non-Small Cell Lung Cancer
22 Sep 2022 23:06 GMT
… In this study, lung cancer radiotherapy resistant cells were … -small cell lung cancer; SCLC, small cell lung cancer; DEGs, differentially … Syed MA. MicroRNA in lung cancer: role, mechanisms, pathways … acquired crossresistance to doxorubicin and radiation in …
-
TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma
21 Nov 2022 13:00 GMT
… of YH001, envafolimab and doxorubicin in the common sarcoma … combination with envafolimab and doxorubicin in advanced or metastatic … of YH001, envafolimab and doxorubicin in patients with leiomyosarcoma … for the treatment of lung cancer; and TJ004309, a …
-
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
11 Sep 2022 09:56 GMT
… non-small cell lung cancer were treated and … 63.6%.
About lung cancer
Lung cancer is the leading cause … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … and paclitaxel followed by doxorubicin or epirubicin and …
-
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
11 Sep 2022 09:29 GMT
… non-small cell lung cancer were treated and … 63.6%.
About lung cancer
Lung cancer is the leading cause … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … and paclitaxel followed by doxorubicin or epirubicin and …
About
© 1995-2023